Halozyme Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| RV7.F | BMRN | LGND | REGN | URGN | ROIV | |
|---|---|---|---|---|---|---|
| Market cap | 13.05B | 11.06B | 6.32B | 96.28B | 1.40B | 27.61B |
| P/E (TTM) | 39.2 | — | 127.0 | 20.6 | — | — |
| Forward P/E | 43.9 | 9.0 | 25.9 | 13.2 | 10.4 | -27.5 |
| Price/book | 102.6 | 1.8 | 6.6 | 2.8 | -13.2 | 6.5 |
| Dividend yield | — | — | — | 0.40% | — | — |
| 1-year change | +94.51% | +10.20% | +51.82% | +51.10% | +78.15% | +85.85% |
| Today | +1.23% | +2.64% | +0.83% | −4.39% | −16.45% | +6.08% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All RV7.F news ›Halozyme Therapeutics (HALO) Q3 earnings report preview: what to look for
Biopharmaceutical drug delivery company Halozyme Therapeutics HALO will be announcing earnings results this Thursday after market hours. Here’s what you need to know. Halozyme Therapeutics beat analysts’ revenue expectations last quarter,…
Head-To-Head Comparison: Valion Bio, Inc. Common Stock (NASDAQ:VBIO) versus Halozyme Therapeutics (NASDAQ:HALO)
Posted by Tristan Rich on Oct 30th, 2026 Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) and Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) are both healthcare companies, but which is the better stock? We will compare…
Stocks To Watch: Halozyme Therapeutics Sees RS Rating Rise To 92
BREAKING: Futures Rise; Musk Warns On Neocloud Rivals Investors.com will undergo scheduled maintenance from 6:00 PM ET to 9:00 PM ET and some features may be unavailable. We apologize for any inconvenience. On Thursday, Halozyme…
Halozyme Therapeutics, Inc. (HALO) – What Are Researchers Saying About This Stock?
Posted by Defense World Staff on Oct 25th, 2026 Check Out Our Latest Stock Report on Halozyme Therapeutics Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and…
Halozyme Therapeutics, Inc. $HALO Stock Position Cut by First Citizens Bank & Trust Co.
Posted by Defense World Staff on Oct 18th, 2026 Here are the key news stories impacting Halozyme Therapeutics this week: View Our Latest Report on HALO Halozyme licenses its technology to pharmaceutical and biotechnology companies, which…
Inside Edge’s Todd Gordon: Halozyme Therapeutics are beating estimates; raised full-year guidance
CNBC Inside Edgeâs Todd Gordon: Halozyme Therapeutics are beating estimates; raised full-year guidance
Halozyme Therapeutics (NASDAQ:HALO) Stock Price Up 5.9% After Analyst Upgrade
Posted by Sarita Garza on Oct 14th, 2026 View Our Latest Stock Report on Halozyme Therapeutics The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The business has a 50-day moving average…
Halozyme Therapeutics Wins Injunction Barring Manufacture, Sale of Merck's Keytruda SC in Multiple EU Markets
... Merck & Co., Inc. Halozyme Therapeutics Wins Injunction Barring Manufacture, Sale of Merck's Keytruda SC in Multiple EU Markets Published on 10/07/2026 at 08:48 am EDT Latest news about Merck & Co., Inc. Chart Merck & Co., Inc. Income…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- defenseworld.net2
- themarketsdaily.com2
- cnbc.com1
- investors.com1
- marketscreener.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.